Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Overview of attention for article published in Journal of Clinical Oncology, March 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

policy: 1 policy source
twitter: 6 X users
weibo: 1 weibo user

facebook: 1 Facebook page
guideline: 3 clinical guideline sources

Readers on

mendeley: 89 Mendeley

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 158,546 followers.

GI Events in Bevacizumab Phase III Trial: Original Report http://t.co/GwSuhkNccJ #JCO #gyncsm

Risk factors for bowel perforation from GOG 218 published in JCO #sgo2014 http://t.co/qArOUBwKYD

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.